GSK Extends Tender Offer for HGS
Human Genome Sciences has once again rejected GSK's unsolicited tender offer after the UK-based pharmaceutical group extended the deadline until June 29th.
GlaxoSmithKline (GSK) has extended the deadline for its hostile bid for Human Genome Sciences (HGS).
The UK-based pharmaceutical group is offering $13 per share in cash and has extended its tender offer to acquire all outstanding shares until 17:00 (New York City time) on Friday June 29th 2012.
Previously, the offer was scheduled to expire at midnight on June 7th.
GSK still believes the offer represents "full and fair value", as it corresponds to a premium of 81 per cent to HGS' closing share price of $7.17 on April 18th 2012.
The company said in a statement: "GSK continues to believe that now is the appropri
Related News
-
News Strategies for managing an outsourcing partner
Robust oversight linked to increased efficiency and better communication with outsourcing partners. -
News Updated: CPHI North America 2022 Blog
Follow along for live updates from CPHI North America, taking place in Philadelphia, PA from May 17-19. -
News Greater standardisation needed for effective ESG reporting - Expert panel
Increased transparency and standardisation in ESG reporting frameworks is emerging as a key requirement for investors. -
News MedPharm: Increased investment driving developments in topical drugs market
We caught up with MedPharm at CPHI North America to discuss opportunities in the topical and transdermal products space. -
News Pharmapack Awards 2022: Winners Revealed
The jury assessed a wide range of industry-changing innovations in packaging and drug delivery, ultimately selecting seven winners. -
News What it means to be 'At the heart of Pharma'
Informa Markets colleagues explain the motivations behind CPHI’s rebrand. -
News CPhI Podcast Series: Leveraging data science for sustainable autoinjector development
Environmental impact is an area of increasing focus for the pharma and biopharma industries, with companies like Merck, Pfizer and GlaxoSmithKline setting ambitious targets for carbon neutrality and laying plans for waste reduction. -
News Thermo Fisher and Charles River join consortium using robotics to produce cell therapies at scale
The Consortium aims to increase the scale of cell therapy manufacturing to a level impossible with current manual processes.
Position your company at the heart of the global Pharma industry with a CPhI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPhI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance